Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

A precursor to remdesivir shows therapeutic potential for COVID-19

A new study points to the potential to use the remdesivir precursor, GS-441524, as a treatment choice for COVID-19.

9 Feb 2021

Novel hybrid device to boost research on metastatic process of breast cancer cells

European researchers are working on a novel hybrid device to better understand the metastatic process of cancer cells travelling from breast to bone and fast screen new drugs against it.

6 Feb 2021

Ivermectin may not be the ‘silver bullet’ antiviral against COVID-19

A team of researchers based in Peru and the U.S. recently examined the role of the anti-parasitic drug ivermectin in treating COVID-19.

1 Feb 2021

Gyros Protein Technologies introduces Gyrolab Bioaffy 4000 CD to extend sensitivity of immunoassay CD range

Gyros Protein Technologies AB today announced the introduction of Gyrolab® Bioaffy™ 4000 CD for immunoassay applications in biotherapeutic workflows.

From Gyros Protein Technologies AB 27 Jan 2021

A new handbook for treating infections in pregnant patients

Pregnancy and Anti-Infective Agents is a concise clinical reference that facilitates health consultants and professionals for determining treatment options for some common prenatal and postpartum infections during pregnancy and the puerperium in patients.

4 Jan 2021

Study examines how obesity affected postpartum hemorrhage outcomes at a tertiary care center

Postpartum hemorrhage, or excessive bleeding after delivery, is still one of the leading causes of severe maternal injury and death in the United States. And the rise in obesity among pregnant women has been linked to increased rates of this potentially serious, largely preventable obstetric complication.

22 Dec 2020

Novel SARS-CoV-2 neutralizing antibody enters Phase 1/2a clinical study

Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody.

18 Dec 2020

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Novel menin-KMT2A inhibitor appears to be safe and well-tolerated. FLT3 inhibitor plus low-dose chemotherapy shows promising efficacy and safety. Results represent encouraging news on hard-to-treat AML subtypes.

7 Dec 2020

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Roswell Park Comprehensive Cancer Center's Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

7 Dec 2020

Minimally invasive technique can help extract dermal interstitial fluid for diagnostic applications

Using an array of tiny needles that are almost too small to see, researchers have developed a minimally invasive technique for sampling a largely unexplored human bodily fluid that could potentially provide a new source of information for routine clinical monitoring and diagnostic testing.

25 Nov 2020

Trial results show CAB LA is more effective in preventing HIV acquisition in women

The HIV Prevention Trials Network study (HPTN 084) on the safety and efficacy of the long-acting injectable antiretroviral drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women, was stopped early by the trial Data and Safety Monitoring Board (DSMB) as results showed CAB LA to be highly effective in preventing HIV acquisition.

10 Nov 2020

Remdesivir metabolite GS-441524 inhibits SARS CoV-2 in mouse model, finds study

This new study titled, "Remdesivir Metabolite GS-441524 Efficiently Inhibits SARS-CoV-2 Infection in Mouse Model," was released online as a preprint on the bioRxiv* server, prior to undergoing the peer-review process.

2 Nov 2020

Lianhuaqingwen capsule is effective for treating COVID-19 pneumonia

Lianhuaqingwen (LHQW) capsule, a herb medicine product, has been clinically proved to be effective in coronavirus disease 2019 (COVID-19) pneumonia treatment. However, human exposure to LHQW components and their pharmacological effects remain largely unknown.

28 Oct 2020

Important structures of SARS-CoV-2 PLpro protease

The pandemic of coronavirus disease 2019 (COVID-19) is changing the world like never before. This crisis is unlikely contained in the absence of effective therapeutics or vaccine.

27 Oct 2020

Nasal spray formulation of ivermectin for COVID-19 shows promise in pigs

Researchers in Argentina have conducted a pre-clinical study demonstrating the safety and pharmacokinetic performance of a new nasal spray formulation designed to suppress the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

26 Oct 2020

Small molecules block SARS-CoV-2 spike-ACE2 attachment

The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.

26 Oct 2020

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain could guide design of antiviral agents

The outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus continues to cause human infection and mortality worldwide. Currently, there are no specific viral protein-targeted therapeutics available.

20 Oct 2020

Researchers develop a molecular docking based webserver to predict drug targets

A highly effective drug therapy is urgently required to combat coronavirus disease 2019 (COVID-19). The authors of this article have developed a molecular docking based webserver, namely D3Targets-2019-nCoV, with two functions, one is for predicting drug targets for drugs or active compounds observed from clinic or in vitro/in vivo studies, the other is for identifying lead compounds against potential drug targets via docking.

20 Oct 2020

In vitro BA-LRA can help detect small molecule drugs for drug-induced liver injury

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the publication of research describing the use of HEPATOPAC® cultures with a targeted in vitro assay to identify small molecule drugs with high potential for drug-induced liver injury (DILI).

13 Oct 2020

Researchers identify a promising method to treat multiple sclerosis

Seema Tiwari-Woodruff, a professor of biomedical sciences in the School of Medicine at the University of California, Riverside, and her colleagues have received a grant of $373,000 from the National Multiple Sclerosis Society for a project in which her lab will select the five best candidate compounds to speed up nerve impulses, a promising new avenue to treat multiple sclerosis.

1 Oct 2020